down 10% this month. sick. Not looking good but consistent. It would need to go up almost 150% to get to where it was 12mths ago.
There can be no good news. Starting trials is not news. Completing them successfully and with a demonstrable advantage and the commercial prospect of production and sales evades this sluggish performer.
